Bridging the Gap: Conference Workbook [International Conference on AIDS (12th: 1994: Geneva, Switzerland)]

Wednesday, July 1

POSERSESSINTak 2

32377 Patient adherence to antiretroviral therapy
Nikola Ostrop*; K. Hallett; MJ. Gill, Canada
32378 Adherence to antiretroviral medications in HIV-infected children:
A collaborative approach with guidelines for care
Ann-Margaret Dunn*; J. Navarra; J. Cervia, USA
32379 Self reported treatment adherence and drug/alcohol use are
associated with virologic outcomes in CCTG 570:
A clinical strategy trial of HIV RNA antiretroviral (ARV) monitoring
Richard Haubrich*; Susan Little; M. Dube; D. Forthal; G. Beall;
C Kemper; J. Hwang; J.A. McCutchan, USA
32380 Adherence and antiretroviral responses to highly active
antiretroviral therapy (HAART) in patients infected with
human Immunodeficiency Virus (HIV):
Comparison between an outpatient clinic and a clinical trials unit
Terhi Heindsmdki*; Q. Shi; T Creagh; U. Mathur-Wagh; A. Marshak;
T. Kanmaz; D. Mildvan, Finland
32381 The Midwest AIDS Training and Education Partners (MATEP)
Adherence Initiative: Rationale and Goals
Bonnie Lubin*; N. Linsk; R. Sherer; B. Schechtman, USA
32382 Towards a new approach for the assessment of adherence to therapy
Victoria Gordillo*; R. Fernandez; B. Ramiro; A. Hoyos, Spain
32383 Service delivery models for treatment adherence to combination
antiretroviral therapy
Mark Waters*; D. Hoos; B.D. Agins; K.S. Savicki; R. Glaros; B.S. Devore;
S.E. Chorost, USA
32384 Patient compliance on combination HIV antiretroviral therapies
John Quirk*;. Wilks, UK
32385 Role of compliance in the efficacy of highly active antiretroviral therapy
(HAART) among a Caribbean cohort of unselected patients
Sylvie Abel*; Guy Sobesky;A. Cabid; G. Conlan-Nayaud; A. Durocher,
France
32386 Compliance in HIV-Comportamenti da Modificare Per La
Incrementazione della Adesione Necessaria alle Cure Erogate in HIV
Vittorio Agnoletto*; Lital Hollander; G. Calvi; A. Liberati; S. Spinsanti;
CL. Cazzullo; M. Clerici, Italy
32387 Cognition and HIV Adherence
Inge B. Corless*; WL. Holzemer; J.G. Turner; K.M. Nokes; M.A. Brown; G.M.
Powell-Cope;J. Inouye, USA
32388 The value of early parameters of adherence in predicting successful
response to highly active antiretroviral therapy (HAART)
Pablo Tebas*; M.C. Royal; CJ. Fichtembaum; M.K. Klebert; M. Arens;
I. Stoilov; WG. Powderly, USA
32389 Adherence to highly active antiretroviral therapy among HIV-infected
patients of the inner city
Barbara E. Johnston*; K. Ahmad; C. Smith; D.N. Rose, USA
32390 Protease Inhibitors (PI) are associated with viral load suppression
in HIV+ Homeless and Marginally housed (H/M) adults
David Bangsberg*; A.R.Zolopa; E. Charlebois; F.M. Hecht; M. Holodniy; T.C.
Merigan; A.R. Moss, USA

32391 Protease inhibitors and recreational drugs: a group approach
to harm minimisation and medication adherence
Barbara Hedge*; B. Major, UK

32392 Adherence to antiretroviral therapy IN HIV-infected patients
Pilar Bachiller*; Francisco Rodriguez Arrando; G. Liceaga; J.A. Iribarren;
E. Olloquiegui; M.C. Ariz; B. Odriozola; M.J. Barcia, Spain
32393 Nevirapine (NVP) + Didanosine (DDI) + lamivudine (3TC) - First
experience with a once-daily dosing antiretroviral combination therapy
Hiedemarie Pernerstorfer-Schoen*; U. Hein; S. Thoeny; E. Tschachler;
G. Stingl; A. Rieger, Austria
32394 The development of effective media campaigns to encourage
compliance with anti HIV treatments
Paul Ward*; L. Power;J. Grimshaw, UK
32395 The health care experiences of HIV-positive transgendered persons
can influence adherence to HIV antiretroviral therapy
Am J. Schilder*; Sandra Laframboise; R.S. Hogg; I. Goldstone; T Trussler;
M.T Schecter; M. V O'Shaughnessy, Canada
32396 Adherence to antiretroviral therapy:The french ministry of health policy
Sophie Fegueux*; G. Pele; D. Bessette; S. Jullian; M. Sainte Marie;
C. Belingard-Jeybach; M. Ballereau, France
32397 A multi-disciplinary approach to maximize patients'adherence to
Highly Active Antiretroviral Therapy (HAART) for HIV-infection
Jaime Hernandez*; Christine Teague; Y Lane; J.E. Hernandez, USA
32398 A survey evaluating pharmacy-related resources and their relation
to drug adherence
Patrick D.O. Nemecheck*; David W.B.S.R. Tritle, USA
32399 Compliance with reverse transcriptase inhibitors or combination
therapy among HIV+ women in Sao Paulo, Brazil
Vera Paiva*; N. Santos; E.M. Ventura-Filipe; N. Hearst; A. Reingold,
Brazil, USA
32400 Obstacles in treatment adherence: Patient reasons
Mario Burgos*; N.S. Revsin; A. Vilas; L. Fontan, Argentina
32401 Adherence to ACTG 076 regimen in a developing
country-Porto Alegre, Brazil
Regis Kreitchmann, Brazil
32402 Prevention of losses to follow up during clinical trials
Jose Luis Valdespino Gomez*; Leticia Dolores Ferreyra Reyes;
V Campos Hernandez; J. Martinez Badillo; M.E. Jimenez Corona;
M.E. Mayar Maya; M.L. Garcia Garcia; M. Palacios Martinez, Mexico
32403 Factors associated in a hispanic cohort with effective adherence
and desired clinical results in patients with triple antiretroviral
therapy (including one PI)
Marisol Martinez*; Antonio Marques; Jennifer Valdes; Jorge Santana,
Puerto Rico
32404 Factors which influence adherence to the use of protease inhibitors
Jucara Arabe*; N.PM. Rubini; A.C.A. Rodrigues; D.WC. Leal;
E.H.S. Freitas; F.S. Sion; C.A. Morais-de-sa, Brazil
32405 The CMA Experience: Applying combination antiretroviral therapy
in a US inner city, advanced AIDS population.Will viral rebound
translate to increased costs?
Donna Gallagher*;J.A. Helliger; R.J. Master, USA
32406 Protease Inhibitors (PI) in the HIV+ homeless and Marginally
Housed (H/M):Good adherence but rarely prescribed

David Bangsberg*;M. Robertson;E. Charlebois;J. Tulsky; FM. Hecht;
J. Bamberger; A.R. Moss, USA

148

12th World AIDS Conference Geneva